Categories Health Care, LATEST
Ocean Biomedical (OCEA) announces $134 million financial backing for innovative research and IND filings
The company has partnered with some of the premier investment institutions in the healthcare space
Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company that works with research universities and medical centers for developing and commercializing their discoveries, said it has secured financial backing from investment institutions for innovative research and Investigational New Drug Application filing. It also provided updates on important company activities.
$134 Mln
The company has partnered with some of the premier investment institutions in the healthcare space, which has led to a secure and growing runway to continue its important scientific innovations. The funding includes a $59 million committed backstop by Vellar Opportunity Fund SPV LLC and a common stock purchase agreement with White Lion Capital LLC, which provides that White Lion Capital is committed to purchasing Ocean’s common stock with an aggregate gross purchase price of up to $75 million. That brings the total current investment to $134 million.
Ocean’s co-founder and chairman Dr. Chirinjeev Kathuria said, “This financing will provide Ocean Biomedical with a stronger capital position, enabling us to move forward quickly towards IND filings and potentially deliver important solutions to end suffering and save hundreds of thousands of lives.”
There is $123.9 million in past and ongoing grants, in use to enable first-in-class drug and vaccine candidates that make up Ocean’s initial core portfolio in oncology, fibrosis, and infectious disease.
“We are appreciative of the support investors are providing so we can move our programs forward,” said Suren Ajjarapu, a director of Ocean Biomedical.
Commenting on the financing, Ocean’s chief executive officer Elizabeth Ng said, “We’re immensely pleased with the progress we’re making as a Company. Our portfolio of drug and vaccine candidates continues to accrue scientific merit, and our relationships with both institutional and retail investors are growing increasingly robust.”
Notice of Allowance
Last week, the company’s scientific co-founder Jonathan Kurtis received a Notice of Allowance from the United States Patent and Trademark Office for his U.S. patent application covering a therapeutic and prophylactic monoclonal antibody that kills falciparum malaria parasites.
The patent allowance will allow the team to pursue the development of the monoclonal antibody as both a potential therapeutic drug for individuals with severe malaria infection as well as a potential short-term prophylactic treatment to prevent malaria infection in travelers, overseas deployed military and government personnel, and individuals living in areas with short malaria transmission seasons.
Looking for more insights on the earnings results? Click here to access the full transcripts of the latest earnings conference calls!
Most Popular
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on
Target (TGT): A look at some of the challenges faced by the retailer in 3Q24
Shares of Target Corporation (NYSE: TGT) stayed green on Thursday, recovering from the stumble it took a day ago after delivering disappointing results for the third quarter of 2024 and